| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 1/6 |
| Dividends | 3/6 |
EXE Stock Overview
Extendicare Inc., through its subsidiaries, provides care and services for seniors in Canada.
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$7.17 |
| 52 Week High | CA$8.71 |
| 52 Week Low | CA$6.06 |
| Beta | 1.36 |
| 1 Month Change | 0.28% |
| 3 Month Change | -0.42% |
| 1 Year Change | 17.16% |
| 3 Year Change | -0.42% |
| 5 Year Change | -30.66% |
| Change since IPO | -1.10% |
Recent News & Updates
Extendicare (TSE:EXE) Has Announced A Dividend Of CA$0.04
Extendicare Inc.'s ( TSE:EXE ) investors are due to receive a payment of CA$0.04 per share on 17th of January. This...
Extendicare (TSE:EXE) Has Re-Affirmed Its Dividend Of CA$0.04
The board of Extendicare Inc. ( TSE:EXE ) has announced that it will pay a dividend of CA$0.04 per share on the 15th of...
Extendicare (TSE:EXE) Is Due To Pay A Dividend Of CA$0.04
Extendicare Inc. ( TSE:EXE ) will pay a dividend of CA$0.04 on the 15th of November. The dividend yield will be 6.6...
Shareholder Returns
| EXE | CA Healthcare | CA Market | |
|---|---|---|---|
| 7D | -0.4% | -2.4% | -2.9% |
| 1Y | 17.2% | -18.4% | 15.9% |
Return vs Industry: EXE exceeded the Canadian Healthcare industry which returned -16.1% over the past year.
Return vs Market: EXE matched the Canadian Market which returned 17.4% over the past year.
Price Volatility
| EXE volatility | |
|---|---|
| EXE Average Weekly Movement | 2.6% |
| Healthcare Industry Average Movement | 10.4% |
| Market Average Movement | 9.8% |
| 10% most volatile stocks in CA Market | 17.4% |
| 10% least volatile stocks in CA Market | 3.7% |
Stable Share Price: EXE is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: EXE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 23,500 | Michael Guerriere | https://www.extendicare.com |
Extendicare Inc., through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; retirement living services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as contract and consulting services to third parties. It operates a net of 121 LTC homes and retirement communities, including 69 owned and 52 contract services, as well as home health care operations under the Extendicare, Esprit Lifestyle Communities, ParaMed, Extendicare Assist, and SGP Purchasing Partner Network brands.
Extendicare Fundamentals Summary
| EXE fundamental statistics | |
|---|---|
| Market Cap | CA$642.16m |
| Earnings (TTM) | CA$27.28m |
| Revenue (TTM) | CA$1.25b |
23.5x
P/E Ratio0.5x
P/S RatioIs EXE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXE income statement (TTM) | |
|---|---|
| Revenue | CA$1.25b |
| Cost of Revenue | CA$1.05b |
| Gross Profit | CA$195.91m |
| Expenses | CA$168.63m |
| Earnings | CA$27.28m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Feb 24, 2022
| Earnings per share (EPS) | 0.30 |
| Gross Margin | 15.70% |
| Net Profit Margin | 2.19% |
| Debt/Equity Ratio | 409.8% |
How did EXE perform over the long term?
See historical performance and comparisonDividends
6.7%
Current Dividend Yield158%
Payout RatioDoes EXE pay a reliable dividends?
See EXE dividend history and benchmarks| Extendicare dividend dates | |
|---|---|
| Ex Dividend Date | Jan 28 2022 |
| Dividend Pay Date | Feb 15 2022 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 23 days |
Does EXE pay a reliable dividends?
See EXE dividend history and benchmarksValuation
Is Extendicare undervalued compared to its fair value and its price relative to the market?
33.8%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EXE (CA$7.17) is trading below our estimate of fair value (CA$10.82)
Significantly Below Fair Value: EXE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: EXE is good value based on its PE Ratio (23.5x) compared to the Canadian Healthcare industry average (34.7x).
PE vs Market: EXE is poor value based on its PE Ratio (23.5x) compared to the Canadian market (13.1x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EXE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EXE is overvalued based on its PB Ratio (5.5x) compared to the CA Healthcare industry average (2.4x).
Future Growth
How is Extendicare forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
-0.2%
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if EXE's forecast earnings growth is above the savings rate (1.6%).
Earnings vs Market: Insufficient data to determine if EXE's earnings are forecast to grow faster than the Canadian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: EXE's revenue is expected to decline over the next 3 years (-0.2% per year).
High Growth Revenue: EXE's revenue is forecast to decline over the next 3 years (-0.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EXE's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Extendicare performed over the past 5 years?
1.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EXE has a large one-off loss of CA$43.0M impacting its September 30 2021 financial results.
Growing Profit Margin: EXE's current net profit margins (2.2%) are lower than last year (2.8%).
Past Earnings Growth Analysis
Earnings Trend: EXE's earnings have grown by 1.6% per year over the past 5 years.
Accelerating Growth: EXE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: EXE had negative earnings growth (-13.3%) over the past year, making it difficult to compare to the Healthcare industry average (-10.6%).
Return on Equity
High ROE: Whilst EXE's Return on Equity (23.49%) is high, this metric is skewed due to their high level of debt.
Financial Health
How is Extendicare's financial position?
Financial Position Analysis
Short Term Liabilities: EXE's short term assets (CA$231.4M) do not cover its short term liabilities (CA$304.5M).
Long Term Liabilities: EXE's short term assets (CA$231.4M) do not cover its long term liabilities (CA$488.4M).
Debt to Equity History and Analysis
Debt Level: EXE's net debt to equity ratio (295.9%) is considered high.
Reducing Debt: EXE's debt to equity ratio has increased from 254.8% to 409.8% over the past 5 years.
Debt Coverage: EXE's debt is not well covered by operating cash flow (19.2%).
Interest Coverage: EXE's interest payments on its debt are well covered by EBIT (4.5x coverage).
Balance Sheet
Dividend
What is Extendicare current dividend yield, its reliability and sustainability?
6.69%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: EXE's dividend (6.69%) is higher than the bottom 25% of dividend payers in the Canadian market (1.6%).
High Dividend: EXE's dividend (6.69%) is in the top 25% of dividend payers in the Canadian market (4.64%)
Stability and Growth of Payments
Stable Dividend: EXE's dividends per share have been stable in the past 10 years.
Growing Dividend: EXE's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (158.3%), EXE's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: EXE's dividends in 3 years are not forecast to be well covered by earnings (575.6% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.0yrs
Average management tenure
CEO
Michael Guerriere (57 yo)
3.25yrs
Tenure
CA$1,713,124
Compensation
Dr. Michael R. Guerriere, MD, MBA, has been the Chief Executive Officer and President at Extendicare Inc. since joined in October 22, 2018. Dr. Guerriere serves as Chairman and Chief Executive Officer of E...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD1.37M) is above average for companies of similar size in the Canadian market ($USD796.65K).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: EXE's management team is considered experienced (2 years average tenure).
Board Members
Experienced Board: EXE's board of directors are considered experienced (6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Extendicare Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Extendicare Inc.
- Ticker: EXE
- Exchange: TSX
- Founded: 1968
- Industry: Health Care Facilities
- Sector: Healthcare
- Implied Market Cap: CA$642.163m
- Shares outstanding: 89.56m
- Website: https://www.extendicare.com
Number of Employees
Location
- Extendicare Inc.
- 3000 Steeles Avenue East
- Suite 103
- Markham
- Ontario
- L3R 4T9
- Canada
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/21 23:38 |
| End of Day Share Price | 2022/01/21 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.